Navigation Links
Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop

p>About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates: Clevudine for the treatment of chronic HBV infection, which is expected to enter US, European and South American Phase 3 registration clinical trials and is already approved for HBV in Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir; R7128, an oral treatment for HCV, in a Phase 1 clinical trial through a strategic collaboration with Hoffmann-LaRoche; and Racivir for the treatment of HIV in combination with other approved HIV drugs, which has completed a Phase 2 clinical trial.

    Contact

    Alan Roemer, Vice President

    Investor Relations & Corporate Communications

    

    Office: (609) 613-4125

alan.roemer@pharmasset.com

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performances or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We describe in greater detail many of the risks that may impact management's expectations under the caption "Risk Factors" in the company's quarterly report on Form 10-Q for the second fiscal quarter ended March 31, 2007 filed with the Securities and Exchange Commission, as well as other filings that the comp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... LAKE, N.J. , May 10 Par Pharmaceutical ... its partner, Glenmark Generics Limited and Glenmark Generics Inc., ... & Co. Inc. that resolves patent litigation related to Glenmark,s ... ends the lawsuit involving a challenge by Glenmark which sought ...
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
Cached Medicine Technology:Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... "My wife suffered neck, back and ... said one of two inventors from Bethel, Alaska. "The ... and neck area. She tried other pillows to little ... assisting in comfort and providing extra sleep." , They ... support the head, neck and back comfortably. This enables ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Market ... Industry, 2009-2019 is a professional and in-depth market ... The report firstly reviews the basic information of ... technology. The report then explores global and China’s ... specification, capacity, production value, and market share etc. ...
(Date:8/30/2014)... 30, 2014 Serving contented clients since ... Profit By Outsourcing is now offering discount for ... company gives emphasize on putting forward the best of ... clients. Their dedicated team of professionals and web developers ... can handle even the critical issues of web development ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... firm announced this week that it has developed a ... improve// the efficacy of chemotherapy drugs and reduce drug ... the US subsidiary of Nitto Denko Corporation, says its ... biocompatible polymer material which can be loaded with therapeutic ...
... study appearing in the Journal of Clinical Oncology reveals ... the lives of patients// with recurrent prostate cancer. ... targeted drugs that scientists at Cedars-Sinai Medical Center in ... in some prostate cancer patients with no previous chemotherapy ...
... of the Medgadget "Most Sci-Fi Sounding Company Name" Award, ... Andara OFS nerve growth stimulation system. ,According ... battery-powered device about the size of a cardiac pacemaker ... attached to the vertebrae at a distance of two ...
... have cautioned about the risk of mercury in canned albacore ... regarding the consumption of tuna in women and children. This ... 8 out of 60 cans of albacore tuna tested contained ... this guideline, four servings of canned albacore tuna per week ...
... A research team has identified certain chemical marks that help ... cells in liposuctioned fat, are best at regenerating// tissue. ... body fat to improve their looks. But unwanted fat also ... heal injuries in the body. ,Uncovering the nature ...
... Medicine have succeeded in producing neurons in vitro ... This is the first time// such an advanced ... from human skin, according to lead researcher Professor ... revolutionary advances in the treatment of neurodegenerative illnesses ...
Cached Medicine News:Health News:New Cost-cutting Cancer Drug Delivery System 2Health News:New Cost-cutting Cancer Drug Delivery System 3Health News:Stem Cells in Liposuctioned Fat can Heal Injuries 2Health News:Scientists Produce Neurons from Human Skin 2